Desentum Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $31.8M

  • Investors
  • 6

Desentum General Information

Description

Developer of a biopharmaceutical platform designed to create novel types of allergen immunotherapy products to fight allergies. The company's platform offers recombinant allergens that can be modified to suppress the histamine release during the desensitization process to safely and effectively treat allergies by reprogramming the immune system's response, enabling healthcare providers to significantly reduce the risk of adverse effects and the time required to treat allergies.

Contact Information

Website
www.desentum.fi
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Tekniikantie 14
  • 02150 Espoo
  • Finland
+358 050
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Tekniikantie 14
  • 02150 Espoo
  • Finland
+358 050

Desentum Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Desentum Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 12-Oct-2026 $31.8M Completed Clinical Trials - Phase 2
9. Later Stage VC Completed Clinical Trials - Phase 2
8. Later Stage VC 20-Feb-2024 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series A) 21-Jan-2022 Completed Clinical Trials - General
6. Secondary Transaction - Private 01-Oct-2021 Completed Clinical Trials - General
5. Later Stage VC (Series A) 01-Nov-2019 Completed Clinical Trials - General
4. Grant 29-Oct-2018 Completed Clinical Trials - General
3. Later Stage VC (Series A) 29-Nov-2017 Completed Clinical Trials - General
2. Later Stage VC (Series A) 31-Dec-2016 $1.99M $7.18M Completed Clinical Trials - General
1. Seed Round 12-Oct-2012 $5.19M $5.19M Completed Clinical Trials - General
To view Desentum’s complete valuation and funding history, request access »

Desentum Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Series A
Series A 2,338,000 $1.14 $1.14 1x $1.14 14.24%
Series B 4,280,796 $0.5 $0.5 1x $0.5 26.07%
To view Desentum’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Desentum Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biopharmaceutical platform designed to create novel types of allergen immunotherapy products to fight all
Biotechnology
Espoo, Finland
15 As of 2026

New York, NY
 

Madrid, Spain
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Desentum Competitors (3)

One of Desentum’s 3 competitors is Easily (Drug Discovery), a Formerly Angel backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Easily (Drug Discovery) Formerly Angel backed New York, NY
Allergopharma España Corporation Madrid, Spain
Paras Biopharmaceuticals Finland Accelerator/Incubator Backed Oulu, Finland
You’re viewing 3 of 3 competitors. Get the full list »

Desentum Patents

Desentum Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2026525506-A A low-allergen variant of ara h 2, a major peanut allergen. Pending 12-Jun-2023
AU-2024305143-A1 Hypoallergenic variants of major peanut allergen, ara h 2 Pending 12-Jun-2023
EP-4724467-A1 Hypoallergenic variants of major peanut allergen, ara h 2 Pending 12-Jun-2023
WO-2024256749-A1 Hypoallergenic variants of major peanut allergen, ara h 2 Inactive 12-Jun-2023
AU-2023348392-A1 Thermosensitive hydrogel composition Pending 26-Sep-2022 A61K9/0024
To view Desentum’s complete patent history, request access »

Desentum Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Desentum Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Springvest Growth/Expansion Minority
Horizon 2020 Government
Cascara Ventures Venture Capital Minority
STO-Rahoitus Corporation Minority
Voima Ventures Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Desentum FAQs

  • When was Desentum founded?

    Desentum was founded in 2011.

  • Where is Desentum headquartered?

    Desentum is headquartered in Espoo, Finland.

  • What is the size of Desentum?

    Desentum has 15 total employees.

  • What industry is Desentum in?

    Desentum’s primary industry is Biotechnology.

  • Is Desentum a private or public company?

    Desentum is a Private company.

  • What is Desentum’s current revenue?

    The current revenue for Desentum is .

  • How much funding has Desentum raised over time?

    Desentum has raised $71M.

  • Who are Desentum’s investors?

    Springvest, Horizon 2020, Cascara Ventures, STO-Rahoitus, and Voima Ventures are 5 of 6 investors who have invested in Desentum.

  • Who are Desentum’s competitors?

    Easily (Drug Discovery), Allergopharma España, and Paras Biopharmaceuticals Finland are competitors of Desentum.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process